Karyopharm Therapeutics | Sustainability Performance
Karyopharm Therapeutics develops and commercializes cancer treatments, focusing on innovative drug therapies for hematologic malignancies and solid tumors.
2008
United States
201 - 500 employees
Pharmaceuticals
$100M - 500M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#5587
Overall#1110
in United States#118
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
- Karyopharm's cancer drug faced clinical efficacy debates in regulatory review.
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$146.0MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
85.6%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
301.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.1
▼ 1.2%
0.1
▼ 3.6%
0.1
▼ 0.7%
1.0
2030Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
46%
Independent Directors
6 out of 13 incl. management
Overall score
32
Environment
33
Social
47
Governance
15
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
